|
|
![]()
|
|
By Louis Garguilo, Chief Editor, Outsourced Pharma
Tim Scott traces the arc of spray drying from its advent to today’s advanced amorphous dispersion technology. Now he's back at it again, pushing the technology to even higher levels of accessibility and productivity.
|
|
|
Outsourced Pharma Live
A panel of industry experts provides advice on making the CDMO relationship work better, and how to optimize your outsourcing outcomes. In October 2022, Outsourced Pharma Live's “What’s Driving The Cell & Gene Therapy Outsourcing Capacity Cycle?” panelists discussed the identified macro and micro trends impacting dealmaking at CDMOs. Exclusive data from BioPlan Associates was also presented. Learn what to be on the lookout for as well as how to prepare and take advantage of (another) life cycle in our industry — this time in the cell and gene therapy space.
|
|
|
![]()
|
|
By Prasanth Sambaraju
Dissolution tests are performed during drug manufacturing to ensure that the drug product meets the standards specified in the United States Pharmacopoeia (USP). This article calculates the probability of passing the USP dissolution test using Microsoft Excel, and it can be modified for any combination of Q, mean, and standard deviations.
|
|
|
By Shriya Bhatkhande, BioPlan Associates
For yet another year, COVID-19 and pandemic-related factors shaped the biopharmaceutical industry. It stretched supply chains and claimed qualified staff who otherwise would have been developing other drugs. BioPlan Associates, which publishes an annual industry survey, looks back on the biggest trends of 2022.
|
|
|
Article
|
By Kate Hammeke,
ISR Reports
New relationship dynamics between sponsors and CDMOs contribute to new trends appearing in the outsourced activities and services, as well as the way CDMO selection decisions are made. ISR shares how CDMO selection criteria has changed over the past five years and links the attributes to the Life Science Leader’s CMO Leadership Awards categories.
|
|
Article
|
By Ken Ball,
Pfizer CentreOne
The diversity and agility of API supply chains are key to ensuring that medicines can be manufactured and delivered to patients on time, even in the face of challenges and unforeseen circumstances.
|
|
Article
|
By Nick Pittman, Magnus Wetterhall, and Scott Berger, Ph.D.,
Waters Corporation
With industry-leading scientific expertise and customer support, we have pioneered solutions to some of the most pressing challenges facing customers interested in adopting MAM into their organizations.
|
|
White Paper
|
By Henry George and Lisa Freeman-Cook,
MilliporeSigma
Learn more about a wide range of solutions to facilitate the delivery of gene therapy by addressing the challenges related to viral vector manufacture and scale-up.
|
|
Poster
|
By Cristina Nogueira, Ben M. Alberts, Jordan Wright, Helen Maunder, Kyriacos A. Mitrophanous, Nicholas G. Clarkson, and Daniel C. Farley,
Oxford Biomedica
The TRiP System allows suppression of transgene expression during upstream processes, resulting in enhanced vector yield and purity, simplifying downstream processes.
|
|
Article
|
Pfizer CentreOne
A strategic partner should seek innovation that improves your compound or product’s value. Pfizer CentreOne’s Tom Wilson shares tips for picking the perfect API partner.
|
|
Article
|
inSeption Group
The Cooperativity Program’s goal is to help ISG clients build and strengthen their in-house departments — medical writing or otherwise — to reach their utmost potential.
|
|
Article
|
AGC Biologics
In adherent cell culture, cells are grown while attached to a substrate as monolayers. In suspension cell culture, cells are free-floating in the culture medium. Which offers more benefits?
|
|
White Paper
|
Asymchem
CDMOs face the challenge of integrating novel technologies to deliver cost-effective innovation to the market. How a CDMO responds to the unexpected can determine the success or failure of a project.
|
|
White Paper
|
Pyxant Labs
To truly understand the way novel therapies function in living biological systems, learn about a new dimension of study that has become indispensable: spatial bioanalysis.
|
|
Q&A
|
Lonza
Lonza principal scientist Deanna Mudie, Ph.D., covers the design of dissolution media to support biopredictive dissolution testing and how the properties of a drug and formulation affect performance.
|
|
Q&A
|
Catalent
Biopharmaceuticals tend to be highly unstable. A pilot formulation study at the early drug substance development stage can make things considerably easier at the manufacturing stage.
|
|
Infographic
|
Cytiva
Therapies based on messenger RNA, such as mRNA vaccines, have revolutionary potential. Learn more about key objectives, considerations, and strategies in mRNA manufacturing.
|
|
Webinar
|
Adare Pharma Solutions
Learn how techniques and innovations in taste masking sensory and performance evaluation can help accelerate your formulation development and confirm desired taste profile.
|
|
|
|
|
|
|
|
Syngene International Ltd.
|
|
|
|
|
Argonaut Manufacturing Services
|
|
|
|
|
![]()
|
|
Available On Demand! Throughout the year, chief editor Louis Garguilo brings together industry experts to discuss some of the biggest challenges being faced by both sponsors and CDMOs. Our archived videos can be accessed at any time by registered site users.
|
|
|
|
Connect With Outsourced Pharma:
|
![LinkedIn]()
|
|
|
|
|
|
|
|
